Jenburkt Pharmaceuticals Ltd - 524731 - Intimation Of Record Date And Cut-Off Date
Jenburkt Pharmaceuticals fixed August 28, 2026, as record date for dividend payment for FY26. This date also determines e-voting eligibility for the 41st Annual General Meeting scheduled on September 04, 2026.
May 06 2026 14:05:00
Jenburkt Pharmaceuticals Ltd - 524731 - Announcement under Regulation 30 (LODR)-Change in Management
Jenburkt Pharmaceuticals re-appointed Shri Dilip H. Bhuta as Whole Time Director and CFO for a five-year term, effective April 1, 2027 to March 31, 2032. This re-appointment provides leadership stability and continuity.
May 05 2026 19:05:00
Jenburkt Pharmaceuticals Ltd - 524731 - Board Meeting Outcome for Outcome Of Board Meeting Held On 05Th May, 2026.
Jenburkt Pharmaceuticals board approved the audited financial results for FY26, reporting ₹168.74 crore in revenue and ₹34.74 crore in net profit. The board also declared a final dividend of ₹20.70 per equity share and re-appointed Shri Dilip H. Bhuta as Whole Time Director and CFO for five years.
May 05 2026 19:05:00
Jenburkt Pharmaceuticals Ltd - 524731 - Board Meeting Intimation for Taking On Record The Audited Financial Results For The Quarter And Financial Year Ended On 31St March, 2026 And To Consider Recommendation Of Dividend, If Any.
Jenburkt Pharmaceuticals' Board of Directors will convene on May 05, 2026. The agenda includes approval of audited financial results for Q4 FY26 and the full financial year, along with considering a dividend recommendation.
Apr 28 2026 16:04:00
Read More